Raloxifene Hydrochloride
Product Images NDC 71610-504

4 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 71610-504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 60 mg (71610 0504 60)

Bottle Label 60 mg (71610 0504 60)
Raloxifene Hydrochloride 60 mg tablets packaging label showing a quantity of 90 tablets. The label indicates storage instructions between 20-25 degrees Celsius, manufacturing in Zagreb, Croatia, and packaging by Aphena Pharma Solutions in Cookeville, TN 38506. The label includes barcodes, an NDC number 71610-0504, and states RX Only.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-structure01.jpg)

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-structure01.jpg)
Chemical structure diagram of Raloxifene Hydrochloride showing its molecular components, including aromatic rings and various functional groups.*
FDA Label Image

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-figure01.JPG)

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-figure01.JPG)
Two line graphs depicting total hip mean percentage change from baseline over 24 months after randomization. The first graph compares Raloxifene Hydrochloride versus placebo in Studies NA and EU, showing percentage change trends with error bars. The second graph compares Raloxifene Hydrochloride, placebo, and conjugated estrogens (CE) in Study INT with hysterectomized women, also showing percentage change trends over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.